Regina Fritsche-Danielson

Regina received a PhD in Cardiovascular Physiology/Pharmacology at the University of Gothenburg in 1993. She then continued in academia for eight years.

During this time she worked at the University of Gothenburg, University of Ottawa, University of Queensland and University of Nevada. In 1997 she became Associate Professor at the University of Gothenburg.

Regina has a broad scientific background in human and animal physiology, particularly in cardiovascular physiology. She has published over 60 papers and several review articles and book chapters within the field. She has detailed knowledge in the area of regenerative medicine, atherosclerosis, heart failure and cardiovascular physiology – including human disease pathophysiological mechanisms, medical need, current treatment and related pre-clinical science and capabilities.

During her nineteen years at AstraZeneca, Regina has held a number of increasingly senior roles spanning from project leader roles for drug projects from early target discovery up to Phase II in clinical development to line management and strategic responsibilities.

In January 2011, Regina was appointed Senior Director and strategy area lead for atherosclerotic cardiovascular disease and she was instrumental in establishing the Cardiac Regeneration research area focusing on heart failure. Regina also led AstraZeneca’s first mRNA programme, VEGF-A from start to Phase II clinical development. In 2014, she was appointed Head of Department Bioscience Heart Failure with overall accountability to initiate and progress the portfolio in the cardiovascular and heart failure area.

In 2017, Regina was appointed Vice President and in 2019 she was promoted to Senior Vice President and Global Head of Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D with accountabilities from target discovery through clinical proof of concept across small and large molecules leading a group of +340 individuals across all three R&D sites.